MA: Avista Pharma Completes $4M Agawam Facility Expansion | Trade and Industry Development

MA: Avista Pharma Completes $4M Agawam Facility Expansion

Mar 24, 2017

Avista Pharma Solutions, Inc. (“Avista Pharma”) announced at the annual Interphex global conference in New York City that the $4 million expansion of its 26,000-square foot contract testing facility in Agawam, Massachusetts is now complete. For over 30 years, the Agawam site has provided superior service to pharmaceutical and medical device clients, and as part of an ongoing initiative, these facility and technology upgrades will enable Avista Pharma to deliver additional microbiology, sterility testing, and microbial ID service offerings.

As the result of Avista Pharma’s 2016 capital investment, the improved facility has 4,200 square feet of additional space, featuring a new microbiology laboratory as well as a modular cleanroom area which houses isolator technology and an ISO 6 cleanroom used for sterility testing of medical devices, pharmaceuticals, and biologics. In addition, the laboratory support division has implemented new pass-through autoclaves and labware processing technologies that streamline workflow and complement Avista Pharma’s extensive suite of microbiology services.

The facility’s full range of comprehensive services will continue to include raw material and finished product release testing, ICH stability and storage, container closure integrity testing (CCIT), water system testing and validation, cleanroom monitoring and risk assessments, microbial identification via both MicroSEQ®ID (rapid 16S rDNA sequencing) and Vitek®MS (MALDI-TOF), mycoplasma testing, Antimicrobial Effectiveness Testing (AET), Microbial Enumeration Testing (MET), endotoxin and bioburden testing and disinfectant efficacy qualifications.

“We remain committed to providing best-in-class Microbiology, Analytical Chemistry and Cleanroom services,” said Patrick Walsh, Chief Executive Officer of Avista Pharma. “This investment will complement our existing capabilities and expand our service offerings for our pharmaceutical and medical device clients.”

See Avista Pharma on Facebook,, on Twitter and on LinkedIn

About Avista Pharma Solutions, Inc.

Avista Pharma, a portfolio company of Ampersand Capital Partners, is a contract testing, development and manufacturing organization (CDMO) encompassing over 200,000 square feet of laboratory and manufacturing space across three locations (Agawam MA, Durham NC and Longmont CO), providing pharmaceutical, animal health and medical device clients a broad suite of scientifically-differentiated services ranging from early stage API and Drug Product discovery, development and cGMP manufacturing to stand-alone analytical and microbiology testing support. For more information about Avista Pharma Solutions, Inc., please visit us at

About Ampersand Capital Partners

Ampersand is a middle market private equity firm with a focus on growth equity investments in the healthcare sector. Over the past two decades, Ampersand has managed more than $1 billion in private equity partnerships. Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Additional information about Ampersand is available at

(Click to Expand)